-
Product Insights
NewNet Present Value Model: Palatin Technologies Inc’s PL-9643
Empower your strategies with our Net Present Value Model: Palatin Technologies Inc's PL-9643 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-8177 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-8177 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PL-8177 in Ulcerative Colitis Drug Details:PL-8177 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bremelanotide Acetate in Diabetic Nephropathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bremelanotide Acetate in Diabetic Nephropathy Drug Details: Bremelanotide acetate (Vyleesi) is belongs to class of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vilobelimab in Granulomatosis with Polyangiitis (Wegener’s Granulomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vilobelimab in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vilobelimab in Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-3994 in Diastolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-3994 in Diastolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PL-3994 in Diastolic Heart FailureDrug Details:PL-3994 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Dapagliflozin + Metoprolol) XR in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Dapagliflozin + Metoprolol) XR in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Dapagliflozin + Metoprolol) XR in...
-
Company Profile
Palatin Technologies Inc – Company Profile
Palatin Technologies Inc (Palatin) is a biopharmaceutical company that develops receptor specific peptide therapeutics. The company’s medicines are based on molecules that control the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product Vyleesi, is indicated for the treatment of premenopausal women with hypoactive sexual desire disorder. Palatin clinical pipeline includes melanocortin receptor programs such as PL-8177 MC1r Agonist (oral) for inflammatory bowel disease; PL9643 MCr Agonist for dry eye diseases; PL-8177 MC1r Agonist (systemic) for ulcerative...
Add to Basket -
Company Profile
BioNTech SE – Company Profile
BioNTech SE (BioNTech) is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell and gene therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, malaria, hepatitis B, influenza, and COVID-19. BioNTech uses FixVac and iNeST technology platforms to discover and develop cancer immunotherapies...
Add to Basket -
Company Profile
Acura Pharmaceuticals Inc – Company Profile
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops and commercializes products and technologies to prevent the abuse and misuse of medication. Acura’s proprietary technologies include, Aversion, Limitx, and Impede technology. The company’s Limitx technology helps to minimize the risks associated with drug overdose and Aversion technology is to address methods of abuse associated with opioid analgesics. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Its product portfolio includes Oxaydo, an opioid...
Add to Basket -
Product Insights
Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Female Sexual Dysfunction Pipeline Drugs Market Overview Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure, and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy. The female sexual dysfunction pipeline market research report provides comprehensive information...